The management of genital herpesvirus infections in pregnancy has seen many changes over the past decade as we have continued to learn more about the epidemiology of the disease. This article reviews these changes and highlights ongoing controversies. Clinical management schemes are proposed based upon this most recent information. (C) 
The ability to distinguish type-2 glycoprotein G has 11--13 allowed virotyping for research purposes.
However, no reliable commercial assay is available. 29 NEONATAL OUTCOMES Neonatal I--ISV infections can be life-threatening events with significant ocular and neurologic sequelae. These sequelae include microophthalmia, retinal dysplasia, chorioretinitis, microcephaly, mental retardation, seizure, apnea, and coma. Infections usually arise from direct contact with the virus during passage through the birth canal or from ascending infections after rupture of the membranes. Approximately 10% of cases arise postnatally from direct contact with parents or caretakers after delivery. 4 Less commonly, infections may occur as congenital infections after transplacental passage of the virus. 3'31 Neonatal infections may be disseminated, localized, or asymptomatic. Disseminated illness more frequently follows primary infections and may have a 50-60% mortality with serious neurologic sequelae in 50% of survivors. 5 Infections with I--ISV-2 appear to be associated with a worse prognosis. 32 The prognosis also appears to be worsened by delay in the initiation of antiviral agents. 
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